

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-29. (Canceled)

30. (Presently Amended) A peptide analogue comprising at least seven consecutive amino acids selected from residues 86 to 99 of human myelin basic protein as recited in SEQ ID NO:3, including residue 91, wherein the L-lysine at position 91 is altered to another amino acid, wherein the peptide analogue comprises not more than 20 amino acids, and wherein the N-terminal amino acid and/or the C-terminal amino acids of the peptide analogue are ~~altered to another amino acid~~ D-amino acids, such that upon administration of the peptide analogue *in vivo* proteolysis is reduced.

31. (Previously Presented) The peptide analogue of claim 30, wherein the N-terminal or the C-terminal amino acid is a D-amino acid.

32. (Original) The peptide analogue of claim 30 wherein L-lysine at position 91 is altered to a non-conservative amino acid.

33. (Original) The peptide analogue of claim 30 wherein residue 91 is altered to D-lysine.

34. (Original) The peptide analogue of claim 30 wherein residue 91 is altered to an amino acid selected from the group consisting of arginine, asparagine, histidine, leucine, serine, glycine, glutamic acid, phenylalanine, alanine and D-lysine.

35.- 72. (Canceled)

73. (Previously Presented) A peptide analogue comprising at least seven consecutive amino acids selected from residues 86-99 of human myelin basic protein as recited in SEQ ID NO:3, including residue 91, wherein the L-lysine at position 91 is altered to another amino acid, further comprising alterations of one to three additional residues selected from residues 86-90, 92-96, 98 and 99 to another amino acid, and wherein the peptide analogue comprises not more than 20 amino acids.

74. (Previously Presented) A composition comprising a peptide analogue according to claim 30 or 73 in combination with a physiologically acceptable carrier or diluent.